Core Insights - iRhythm Technologies reported a record revenue of $186.7 million for Q2 2025, reflecting a 26.1% increase compared to $148.0 million in Q2 2024, driven by strong demand for Zio services and market penetration of Zio AT [4][8] - The company achieved a gross profit of $132.9 million, up 28.4% from $103.5 million in the same quarter last year, with a gross margin of 71.2%, an increase from 69.9% [5][8] - iRhythm's net loss narrowed to $14.2 million, or a diluted loss of $0.44 per share, compared to a net loss of $20.1 million, or a diluted loss of $0.65 per share in Q2 2024, attributed to revenue growth and operational efficiencies [7][8] Financial Performance - Revenue for Q2 2025 was $186.7 million, a 26.1% increase from $148.0 million in Q2 2024 [4][8] - Gross profit reached $132.9 million, a 28.4% increase from $103.5 million in the same period last year, with a gross margin of 71.2% [5][8] - Operating expenses for Q2 2025 were $151.6 million, up from $126.5 million in Q2 2024, with adjusted operating expenses at $145.2 million compared to $125.2 million [6][8] Strategic Developments - The company executed a strategic partnership with Lucem Health to enhance early identification of undiagnosed arrhythmias, leveraging AI for predictive and preventive care [8] - iRhythm's annual revenue guidance for 2025 has been increased to a range of $720 million to $730 million, with an expected adjusted EBITDA margin of approximately 8.0% to 8.5% [10][8] Cash Position - As of June 30, 2025, iRhythm reported unrestricted cash, cash equivalents, and marketable securities totaling $545.5 million [9][8]